CN108261539A - A kind of composition, preparation method and the usage for antithrombotic - Google Patents
A kind of composition, preparation method and the usage for antithrombotic Download PDFInfo
- Publication number
- CN108261539A CN108261539A CN201810161726.1A CN201810161726A CN108261539A CN 108261539 A CN108261539 A CN 108261539A CN 201810161726 A CN201810161726 A CN 201810161726A CN 108261539 A CN108261539 A CN 108261539A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- antithrombotic
- concentration
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 41
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 51
- 235000013557 nattō Nutrition 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 18
- 102000016942 Elastin Human genes 0.000 claims abstract description 14
- 108010014258 Elastin Proteins 0.000 claims abstract description 14
- 229920002549 elastin Polymers 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940086319 nattokinase Drugs 0.000 claims description 17
- 108010073682 nattokinase Proteins 0.000 claims description 17
- 238000005238 degreasing Methods 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 239000000845 maltitol Substances 0.000 claims description 11
- 235000010449 maltitol Nutrition 0.000 claims description 11
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 11
- 229940035436 maltitol Drugs 0.000 claims description 11
- 229920002307 Dextran Polymers 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 229940026314 red yeast rice Drugs 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 238000005360 mashing Methods 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 229940091250 magnesium supplement Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229940127217 antithrombotic drug Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 35
- 210000004369 blood Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 24
- 150000002632 lipids Chemical class 0.000 abstract description 17
- 230000036737 immune function Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of composition, preparation method and the usage for antithrombotic, belongs to biotechnology.For the composition of antithrombotic, in parts by weight, including 1-10 parts of natto powder 10-40 parts of concentration and stripped tuna Elastin peptide.Above-mentioned concentration natto powder and stripped tuna Elastin peptide are mixed to get to the composition for antithrombotic.Purposes of the composition made from this preparation method in drug, health products or the food such as new resource food for antithrombotic is prepared is wider, and health, safety have no toxic side effect, and antithrombotic effect is good, and can reducing blood lipid, increase the immune function of patient.
Description
Technical field
The present invention relates to biotechnology, in particular to a kind of composition, preparation method for antithrombotic
And purposes.
Background technology
The life and health of the thrombotic diseases serious threat mankind, incidence are in first of various diseases, the cause of disease and hair
Interpretation of the cause, onset and process of an illness system is sufficiently complex, not yet illustrates completely so far, it is now recognized that platelet function abnormality and vascular endothelial cell damage are blood
An important factor for bolt formation.Thrombosis is one of main pathogenic of ischemic cardiovascular and cerebral vascular disease, research shows that, cerebral ischemia
When, platelet function abnormality is hyperfunction, and blood is in hypercoagulative state, is the one of the major reasons for causing secondary brain injury, it is seen then that
It hematoblastic activation and is gathered in thrombosis and plays an important role.
People constantly look for that the drug of side effect can be reduced to prevent thrombotic diseases, existing antithrombotic for a long time
Side effects of pharmaceutical drugs are larger.
Invention content
The purpose of the present invention is to provide a kind of composition for antithrombotic, health, safety have no toxic side effect, anti-blood
Bolt effect is good, can reducing blood lipid, increase the immune function of patient.
Another object of the present invention is to provide a kind of preparation method of the above-mentioned composition for antithrombotic, simple, side
Just.
The third object of the present invention is that providing a kind of above-mentioned composition for antithrombotic is preparing for antithrombotic
Purposes in drug, health products or food such as new resource food.
Realization that the present invention adopts the following technical solutions：
A kind of composition for antithrombotic, in parts by weight, including natto powder 10-40 parts of concentration and stripped tuna elasticity
1-10 parts of protein peptides.
Further, in preferred embodiments of the present invention, the content of the Nattokinase of above-mentioned concentration natto powder is：
3200FU/g >=Nattokinase >=3000FU/g.
Further, in preferred embodiments of the present invention, the content of the Nattokinase of above-mentioned concentration natto powder for >=
7000FU/g。
Further, in preferred embodiments of the present invention, above-mentioned composition further includes maltitol, microcrystalline cellulose and black
Skin of beancurd powder；
Preferably, in parts by weight, maltitol 20-40 parts, 20-30 parts of microcrystalline cellulose and Testa sojae atricolor powder 1-
10 parts.
Further, in preferred embodiments of the present invention, above-mentioned composition is further included selected from yeast beta-dextran, hard
At least one of sour magnesium, maltodextrin, red yeast rice.
Preferably, in parts by weight, yeast beta-dextran 5-15 parts, 0.5-5 parts of hard magnesium, maltodextrin 0-
30 parts, 1-10 parts of red yeast rice.
A kind of preparation method of the above-mentioned composition for antithrombotic mixes all raw materials of composition according to formula
It arrives.
Further, in preferred embodiments of the present invention, the preparation method of above-mentioned concentration natto powder is：After soybean boiling
Inoculation bacillus natto to ferment, concentration, is purified and is dried to obtain mashing.
Further, in preferred embodiments of the present invention, above-mentioned concentration is to carry out under conditions of 20-30 DEG C in temperature
20-30min.
Further, it further includes degreasing in preferred embodiments of the present invention, after above-mentioned concentration, before purifying and takes off vitamin
The step of K2.
The above-mentioned composition for antithrombotic is preparing drug, health products or the food such as new resources food for antithrombotic
Purposes in product, preferred agents, health products or food such as new resource food are to give dosage form through gastrointestinal tract, such as oral type dosage form.
The advantageous effect of the composition for antithrombotic that presently preferred embodiments of the present invention provides is：Will concentration natto powder and
Stripped tuna Elastin peptide is used cooperatively, and antithrombotic effect is good, can reducing blood lipid, increase the immune function of patient, and health, peace
Entirely, it has no toxic side effect.
Advantageous effect provided by the present invention for the preparation method of the composition of antithrombotic is：Preparation method is simple, holds
Easy industrialized production.
The above-mentioned composition for antithrombotic is preparing drug, health products or the food such as new resources food for antithrombotic
Purposes in product, obtained product can reducing blood lipid, increase the immune function of patient, and health, safe and free of toxic and side effects.
Specific embodiment
Composition, the preparation method and the usage provided by the present invention for antithrombotic are specifically described below.
A kind of composition for antithrombotic, in parts by weight, including natto powder 10-40 parts of concentration and stripped tuna elasticity
1-10 parts of protein peptides.
Wherein, natto powder can directly decompose thrombus, and every gram of wet natto powder thrombolytic effect is equivalent to urokinase 1600IU.Natto
Powder is up to the action time of thrombus 8-12 hours, and urokinase action time only has 30 minutes.Urokinase can only be injected, and receive
Bean powder, that is, injectable is also orally available, and can play a role in capillary.
Concentration natto powder is for natto powder, the content higher of Nattokinase, the effect of antithrombotic and reducing blood lipid
More preferably.Nattokinase (nattokinase abbreviation NK) is a kind of Proteinkinase, is by receiving in soybean isoflavone by natto strain
A kind of serine protease that beans hay bacillus (Bacillus subtilisl natto) generates has thrombus, reduces
Blood viscosity improves blood circulation, the effects that softening and increase blood vessel elasticity.
In the present invention, the content for concentrating the Nattokinase of natto powder is：3200FU/g >=Nattokinase >=3000FU/g.Also
Can be：The content for concentrating the Nattokinase of natto powder is >=7000FU/g.The content of Nattokinase is higher, antithrombotic and drop
The effect of blood fat is better.The content of Nattokinase is higher, and dose can be relatively reduced.
The effect of stripped tuna Elastin peptide is：Elastin laminin is distributed across main artery, ligamentaum nuchae, skin and lung etc., tool
There are rubber ductility and low elasticity, be widely distributed in the protein hydrolysate of internal organs and tissue.Particularly blood vessel (main artery) is containing about
50% elastin laminin imparts the elasticity of blood vessel.But with advancing age, elastic protein fiber will appear denaturation, break
It splits and reduces, and collagenous fibres can increase, the phenomenon that being hardened so as to cause blood vessel.Stripped tuna elastin laminin is from deep-sea fish
It is extracted in bulbus arteriosus, there is the effect for improving blood vessel elasticity and vascular function.
Preferably, composition further includes maltitol, microcrystalline cellulose and Testa sojae atricolor powder；Wherein, in parts by weight, wheat
1-10 parts of 20-40 parts of bud sugar alcohol, 20-30 parts of microcrystalline cellulose and Testa sojae atricolor powder.
Maltitol, microcrystalline cellulose and Testa sojae atricolor powder can guide concentration natto powder and stripped tuna elasticity to assist ingredient
The stronger antithrombotic efficacy of protein peptides performance, antithrombotic, reducing blood lipid, the antithrombotic effect for making entire composition are more preferable.
Composition is further included selected from least one of yeast beta-dextran, hard magnesium, maltodextrin, red yeast rice；Its
In, in parts by weight, 5-15 parts of yeast beta-dextran, 0.5-5 parts of hard magnesium, 0-30 parts of maltodextrin, red yeast rice
1-10 parts.
Yeast beta-dextran, hard magnesium, maltodextrin, red yeast rice also assist ingredient, wherein, yeast beta-dextran energy
Enough enhance the immunity of human body, the daily dose of yeast beta-dextran is not more than 250mg；Treatment of the red yeast rice to blood fat, thrombus
It is preferable to imitate function, concentration natto powder and stripped tuna Elastin peptide can further be guided to play stronger antithrombotic efficacy, anti-blood
Bolt, reducing blood lipid, the antithrombotic effect for making entire composition are more preferable.
The preparation method of the above-mentioned composition for antithrombotic is to be mixed to get all raw materials of composition according to formula；
Preparation method is simple, easy to operate, and being capable of large-scale industrial production.
Preferably, the preparation method for concentrating natto powder is：Will after soybean boiling be inoculated with bacillus natto to ferment, mashing,
It concentrates, purify and is dried to obtain.More preferably, further include the step of degreasing takes off farnoquinone before purifying, i.e., using soybean as raw material,
Through choose practice, cleaning, inoculation bacillus natto to ferment after boiling, mashing, ultrafiltration, ultralow temperature concentration, degreasing take off farnoquinone, pure
Change (removing dissolvent residual), spray drying, smash, be sieved and be made.
Wherein, the inoculum concentration of bafillus natto is 1%-1.5%, is fermented under conditions of 35-37 DEG C after inoculation
18-24h.Natto homogeneous after fermentation can be enable the Nattokinase in the natto after fermentation to release by mashing, and
And make its assimilation effect more preferable, better anti-thrombus function can be played.
The natto slag after mashing can be filtered out by ultrafiltration, further improve the antithrombotic effect of concentration natto powder
Fruit.Preferably, ultrafiltration is carried out by ultrafiltration membrane.Concentration can be concentrated under ultralow temperature, mainly further improve concentration
The content of Nattokinase in natto powder increases the antithrombotic property of composition.Specifically, concentration be temperature be 20-30 DEG C
Under the conditions of carry out 20-30min.
The step of degreasing takes off farnoquinone is further included before purifying.It is anti-in order to further improve it that degreasing, which takes off farnoquinone,
Thrombus and the function of reducing blood lipid.During degreasing takes off farnoquinone, degreasing takes off farnoquinone and room temperature extraction may be used
Mode carries out, that is, adds in petroleum ether equal solvent and extract 12-24h at room temperature, rear to filter, and takes filter residue.
Degreasing is purified after taking off farnoquinone, and purifying is to add in second in the mixture of farnoquinone is taken off by degreasing
Alcohol, after filter to take filter residue, carry out 3-5 time, obtain pure natto powder, the content of Nattokinase is very high, has and resists well
Thrombus and lipid-lowering effect.
The above-mentioned composition for antithrombotic is preparing drug, health products or the food such as new resources food for antithrombotic
Purposes in product, preferred agents, health products or food such as new resource food are to give dosage form through gastrointestinal tract, such as oral type dosage form.
Dosage form is given through gastrointestinal tract, refers to that pharmaceutical preparation enters gastrointestinal tract after orally taking, play part or whole body work is played through absorption
Dosage form.
The administered dose of composition, drug, health products or the food such as new resource food of the present invention can be 10mg-10g
Active ingredient/kg weight, for example, 200mg active ingredients/kg weight, 3g active ingredients/kg weight, 4g active ingredients/kg bodies
Weight or 10mg active ingredients/kg weight.Composition, drug, health products or the food such as new resource food of the present invention is given
Amount can be that 1-1000mg concentrates natto powder/kg weight, such as 1-400mg concentration natto powder/kg bodies to concentrate in terms of natto powder
Weight, 2-800mg concentration natto powder/kg weight, 3-1000mg concentration natto powder/kg weight or 4-600mg concentrations natto powder/
Kg weight.
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person, the condition suggested according to normal condition or manufacturer carry out.Reagents or instruments used without specified manufacturer is
The conventional products that can be commercially available.
Embodiment
1. animal experiment
1.1 test material
1.1.1 animal
Wistar hyperlipidemia models rat is selected to carry out blood fat reducing function research.
1.1.2 drug and reagent
Concentrate natto powder：Place of production Japan.
Stripped tuna Elastin peptide：Place of production Japan.
Testa sojae atricolor powder：Place of production Japan.
Maltitol：Place of production Japan.
Microcrystalline cellulose,：Place of production Japan.
Maltodextrin：Place of production Japan.
Yeast beta-dextran：Place of production China.Angel Yeast Co., Ltd
Hard magnesium：Place of production China.Anhui Shanhe Medical Accessary Material Co., Ltd.
Red yeast rice：Place of production China.Hangzhou span biotech inc
It is the product that can be bought on the market.
1.2 experiment settings
Composition is set as two factors, each factor is one group.A groups is concentrate natto powder, stripped tuna Elastin peptide.B
Group is maltitol, microcrystalline cellulose and Testa sojae atricolor powder.Experiment is compared by different ratio mode to each factor.
A groups (first chamber) concentrate natto powder and the experiment of stripped tuna elastin laminin peptide combinations
A.1 reducing blood lipid is tested
A.1.1 experimental method
Rat is randomly divided into 6 groups, every group 12.High blood lipid model blank group, 2 groups of comparative example, is implemented 1 group of comparative example
1 group of example, 2 groups of embodiment, 3 groups of embodiment.
Embodiment 1-3 groups are configured to the administration of distilled water suspension oral gavage, high blood according to mouse weight by 1 ingredient equivalent of table
The distilled water of fat blank group gastric infusion same volume is continuously implemented 2 weeks, implement the time for every afternoon a bit.Most it is administered all day
It after one hour, takes a blood sample at room temperature from mouse orbit rear vein beard, collects blood sample about 1.5mL, centrifuged under the conditions of 2500Xg
10min takes serum, is placed in spare in -20 DEG C of refrigerators.
1 blood fat of table tests two kinds of Components Examples
A.1.2 experimental result
Each group of mean people mouse has no the difference of weight passage.
Blood fat result of the test is shown in Table 2
The lipids detection situation of 2 mouse of table
From table 2 it can be seen that the composition of the antithrombotic of embodiment 1 not only reduces the effect of triglyceride and T-CHOL
Good, and compared with comparative example 1,2, component proportion is 10 to 1 embodiment 1, reduces the effect of triglyceride and T-CHOL not
But it is better than the comparative example 1 that any of which component is individually implemented, 2, and consolidate more than both reduction triglycerides and total courage
The summation that alcohol is fallen.Embodiment 1-3 groups compare with model group, can significantly reduce triglyceride and T-CHOL.It is wherein real
It is most apparent to apply 3 groups of effects of example.This experiment shows that A compositions have played good multiplication effect, being capable of notable reducing blood lipid.
In view of the easy recurrent exerbation of hyperlipidaemic conditions, so the maintenance of intermittent phase is particularly significant.Blood fat is fluctuated
Fluctuation is very unfavorable to health, advocates slowly gradually deacidification, keeps stablizing low value for a period of time, makes human body self-recovery generation
Thank to balance.So it is further studied for direction with " reducing blood lipid of walking unhurriedly is adjusted " comprehensively.Change A composition divided doses,
Add B group ingredients：Maltitol, microcrystalline cellulose and Testa sojae atricolor powder carry out proportioning test.
AB.1 experimental methods
Rat is randomly divided into 6 groups, every group 12.4 groups of embodiment, 5 groups of embodiment, 6 groups of embodiment.
It is continuous to be configured to the administration of distilled water suspension oral gavage according to mouse weight by 3 ingredient equivalent of table for embodiment 4-6 groups
Implement 2 weeks, implement the time for every afternoon a bit.After a hour most is administered all day, the vein after mouse orbit at room temperature
Clump blood sampling, collects blood sample about 1.5mL, 10min is centrifuged under the conditions of 2500Xg, takes serum, is placed in spare in -20 DEG C of refrigerators.
3 blood fat of table tests each component embodiment
| Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Concentrate natto powder/mg/kg/d | 100 | 400 | 200 |
| Stripped tuna Elastin peptide/mg/kg/d | 10 | 100 | 50 |
| Maltitol/mg/kg/d | 200 | 300 | 400 |
| Microcrystalline cellulose/mg/kg/d | 300 | 250 | 200 |
| Testa sojae atricolor powder/mg/kg/d | 10 | 50 | 100 |
A.1.2 experimental result
Each group of mean people mouse has no the difference of weight passage.
Blood fat result of the test is shown in Table 4
The lipids detection situation of 4 mouse of table
| Embodiment 4 | Embodiment 5 | Embodiment 6 | It deactivates two weeks | Deactivate surrounding | |
| Triglyceride/mmol/L | 1.42 | 1.44 | 1.45 | 1.43 | 1.41 |
| T-CHOL/mmol/L | 4.41 | 4.32 | 4.38 | 4.33 | 3.89 |
From table 4, it can be seen that after addition maltitol, microcrystalline cellulose and Testa sojae atricolor powder, triglyceride and total is reduced
The effect of cholesterol is still fine, and after two weeks and deactivated surrounding are deactivated, the content of triglyceride and T-CHOL does not have
Increase, illustrate after taking above-mentioned composition, will not rebound, be conducive to the health of patient.
Experimental example
Prepare concentrate natto powder when, carry out respectively degreasing the step of taking off farnoquinone formed experimental group and without
Degreasing takes off the step of farnoquinone in contrast group, and the effect of be used cooperatively with stripped tuna Elastin peptide, detect its reducing blood lipid.
Rat is randomly divided into 6 groups, every group 12.1 group of experiment is respectively divided into, 2 groups of experiment, 3 groups of experiment, 1 group is compareed, is right
According to 2 groups, 3 groups of control.
1-3 groups and control 1-3 groups are tested according to mouse weight, distillation aqueous suspension is configured to by 5 ingredient equivalent of table and fills
Stomach is administered, and the distilled water of hyperlipidemia blank group gastric infusion same volume is continuously implemented 2 weeks, and the implementation time is every afternoon one
Point.It after a hour most is administered all day, takes a blood sample at room temperature from mouse orbit rear vein beard, collects blood sample about 1.5mL,
10min is centrifuged under the conditions of 2500Xg, takes serum, is placed in spare in -20 DEG C of refrigerators.
5 blood fat of table experiment respectively carry out degreasing take off farnoquinone and do not carry out the step of degreasing takes off farnoquinone obtain it is dense
The service condition of contracting natto powder
Experimental result
Each group of mean people mouse has no the difference of weight passage.
Blood fat result of the test is shown in Table 6
The lipids detection situation of 6 mouse of table
| Experiment 1 | Experiment 2 | Experiment 3 | Control 1 | Control 2 | Control 3 | |
| Triglyceride/mmol/L | 1.53 | 1.45 | 1.44 | 1.88 | 1.91 | 1.89 |
| T-CHOL/mmol/L | 4.33 | 4.16 | 3.87 | 6.33 | 6.45 | 6.23 |
As can be seen from Table 6, after concentration natto powder have passed through the step of degreasing takes off farnoquinone, the effect of reducing blood lipid
Further strengthen, the effect of better antithrombotic can be played.
Although illustrate and describing the present invention with specific embodiment, it will be appreciated that without departing substantially from the present invention's
Many other change and modification can be made in the case of spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of composition for antithrombotic, which is characterized in that in parts by weight, including concentration natto powder 10-40 part with
1-10 parts of stripped tuna Elastin peptide.
2. composition according to claim 1, which is characterized in that the content of Nattokinase of the concentration natto powder is：
3200FU/g >=Nattokinase >=3000FU/g.
3. composition according to claim 1, which is characterized in that it is described concentration natto powder Nattokinase content for >=
7000FU/g。
4. according to claim 1-3 any one of them compositions, which is characterized in that the composition further include maltitol,
Microcrystalline cellulose and Testa sojae atricolor powder；
Preferably, in parts by weight, described maltitol 20-40 parts, described microcrystalline cellulose 20-30 parts and the black soya bean
1-10 parts of skin powder.
5. composition according to claim 4, which is characterized in that the composition further include selected from yeast beta-dextran,
At least one of hard magnesium, maltodextrin, red yeast rice；
Preferably, in parts by weight, described yeast beta-dextran 5-15 parts, the hard magnesium 0.5-5 parts described, wheat
It is 0-30 parts of bud dextrin, red yeast rice 1-10 parts described.
It is 6. a kind of if claim 1-5 any one of them is for the preparation method of the composition of antithrombotic, which is characterized in that
All raw materials of the composition are mixed to get according to formula.
7. preparation method according to claim 6, which is characterized in that it is described concentration natto powder preparation method be：It will be big
Bacillus natto to ferment is inoculated with after beans boiling, mashing, concentration, purifies and is dried to obtain.
8. preparation method according to claim 7, which is characterized in that the concentration is in the condition that temperature is 20-30 DEG C
Lower carry out 20-30min.
9. preparation method according to claim 8, which is characterized in that after the concentration, degreasing is further included before purifying
The step of de- farnoquinone.
10. according to claim 1-5 any one of them for antithrombotic composition prepare for antithrombotic drug,
Purposes in health products or food such as new resource food, preferably described drug, health products or food such as new resource food are warp
Gastrointestinal tract gives dosage form, such as oral type dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810161726.1A CN108261539A (en) | 2018-02-27 | 2018-02-27 | A kind of composition, preparation method and the usage for antithrombotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810161726.1A CN108261539A (en) | 2018-02-27 | 2018-02-27 | A kind of composition, preparation method and the usage for antithrombotic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108261539A true CN108261539A (en) | 2018-07-10 |
Family
ID=62774420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810161726.1A Pending CN108261539A (en) | 2018-02-27 | 2018-02-27 | A kind of composition, preparation method and the usage for antithrombotic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108261539A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418851A (en) * | 2020-04-29 | 2020-07-17 | 私诺(北京)健康科技有限公司 | A nutritious food for protecting blood vessel |
| CN115005434A (en) * | 2022-07-20 | 2022-09-06 | 完美（广东）日用品有限公司 | Composition for improving microcirculation, liquid preparation, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300220A (en) * | 1998-03-13 | 2001-06-20 | 人造结缔组织股份有限公司 | Peptide compositions and formulations and use of same |
| CN103404852A (en) * | 2013-07-25 | 2013-11-27 | 苏州萃智新技术开发有限公司 | Functional compound natto health care product |
| CN104855845A (en) * | 2015-06-08 | 2015-08-26 | 周维官 | Natto nutritional health food |
-
2018
- 2018-02-27 CN CN201810161726.1A patent/CN108261539A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300220A (en) * | 1998-03-13 | 2001-06-20 | 人造结缔组织股份有限公司 | Peptide compositions and formulations and use of same |
| CN103404852A (en) * | 2013-07-25 | 2013-11-27 | 苏州萃智新技术开发有限公司 | Functional compound natto health care product |
| CN104855845A (en) * | 2015-06-08 | 2015-08-26 | 周维官 | Natto nutritional health food |
Non-Patent Citations (2)
| Title |
|---|
| UESUGI, YOSHIKO ET AL.: "An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy", 《JOURNAL OF CONTROLLED RELEASE》 * |
| 李虹等: "纳豆溶栓效应的研究", 《食品与发酵工业》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418851A (en) * | 2020-04-29 | 2020-07-17 | 私诺(北京)健康科技有限公司 | A nutritious food for protecting blood vessel |
| CN115005434A (en) * | 2022-07-20 | 2022-09-06 | 完美（广东）日用品有限公司 | Composition for improving microcirculation, liquid preparation, and preparation method and application thereof |
| CN115005434B (en) * | 2022-07-20 | 2023-04-11 | 完美（广东）日用品有限公司 | Composition and liquid preparation for improving microcirculation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6828054B2 (en) | Walnut oligopeptide powder, its preparation method and use | |
| CN102159227B (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN104131057B (en) | Functional white kidney bean polypeptide and preparation method and application thereof | |
| CN106282287A (en) | A kind of method extracting Semen Ginkgo biologically active polypeptide | |
| CN107573405A (en) | A kind of mussel polypeptide extract and preparation method thereof | |
| CN102771620B (en) | Method for producing hydrolyzed brain protein powder and cephalin by grease removal of supercritical carbon dioxide | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN105998072B (en) | Pig brain extract, composition containing pig brain extract and application of pig brain extract | |
| CN109090597A (en) | A kind of auxiliary lower hyperlipidemia, hypertension, hyperglycemia composition and its preparation method and application | |
| CN108261539A (en) | A kind of composition, preparation method and the usage for antithrombotic | |
| KR20210029118A (en) | Pharmaceutical composition comprising anchovy processed product and/or soybean processed product as an active ingredient | |
| CN103301321B (en) | Thrombolytic active polysaccharide mixture preparation technology | |
| CN102659917A (en) | Method for separating and preparing crude protein and enzymolysis peptide from pollen pini | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN106174494A (en) | A kind of compositions and the application in the product preparing nourishing the brain and improving intelligence thereof | |
| CN112715965A (en) | Coconut dietary fiber and preparation method and application thereof | |
| CN104857034A (en) | Functional food for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| TWI590766B (en) | Thrombotic disease prevention preparation | |
| CN107648463A (en) | Chinese medicine composition containing oyster peptide with checking exuberance of yang tonifying yin effect and its production and use | |
| CN110771902A (en) | Composite polypeptide powder and application thereof | |
| CN110856744A (en) | New application of dendrobe polypeptide | |
| CN104739896A (en) | Composite fungal intercellular polysaccharide composition with liver protecting function and preparation method | |
| CN105233250B (en) | A kind of composite biological agent for being used to treat encephalopathy | |
| CN1857348A (en) | Water soluble Chinese angelica extract and its injection and their preparing process | |
| CN101240014A (en) | Lipopeptid composition with physiological activity and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180710 |
|
| RJ01 | Rejection of invention patent application after publication |